Insud Pharma completed the acquisition of the women’s healthcare business from Viatris in a $265m deal.

Insud Pharma, a Spanish multinational pharmaceutical company, completed the acquisition of the women’s healthcare business, primarily related to oral and injectable contraceptives, from Viatris, a global healthcare company, in a $265m deal. "I am very excited about today's announcement as it marks an important milestone in the execution of our overall strategic plan. Not only will this bring to conclusion all of our Phase 1 commitments, including the expected achievement of our deleveraging target of 3 times gross leverage in the first half of 2024, importantly it will also set the Company up extremely well as we enter into our Phase 2 strategy for 2024 and beyond," Scott A. Smith, Viatris CEO.